EPISODE · Mar 1, 2019 · 9 MIN
Gene Editing Is Trickier Than Expected—but Fixes Are in Sight
from Science, Spoken · host SpokenLayer
Of all the big, world-remaking bets on the genome-editing tool known as Crispr, perhaps none is more tantalizing than its potential to edit some of humanity’s worst diseases right out of the history books. Just this week, Crispr Therapeutics announced it had begun treating patients with an inherited blood disorder called beta thalassemia, in the Western drug industry’s first test of the technology for genetic disease. Learn about your ad choices: dovetail.prx.org/ad-choices
What this episode covers
Of all the big, world-remaking bets on the genome-editing tool known as Crispr, perhaps none is more tantalizing than its potential to edit some of humanity’s worst diseases right out of the history books. Just this week, Crispr Therapeutics announced it had begun treating patients with an inherited blood disorder called beta thalassemia, in the Western drug industry’s first test of the technology for genetic disease.
NOW PLAYING
Gene Editing Is Trickier Than Expected—but Fixes Are in Sight
No transcript for this episode yet
Similar Episodes
No similar episodes found.